FAF

(redirected from FANCF)
Also found in: Medical.

FAF

abbr.
financial aid form
Mentioned in ?
References in periodicals archive ?
Genes Tested AtP ALK APC ATM BAP1 BRCA2 BRIP1 BUB1B CDC73 CDH1 CEP57 CHEK2 CYLD DDB2 DICER1 ERCC3 ERCC4 ERCC5 EXT1 EXT2 FANCD2 FANCE FANCF FANCG FANCI GATA2 GPC3 HNF1A HOXB13 HRAS MLH1 MHS2 MSH6 MUTYH NBN PHOX2B PMS1 PMS2 PPM1D PRF1 RAD51D RBI RECQL4 RET RHBDF2 SDHC SDHD SLX4 SMAD4 SMARCA4 TP53 TSC1 TSC2 VHL WT1 BARD1 BLM BMPR1A BRCA1 CDK4 CDKN1C CDKN2A CEBPA DI53L2 EGFR EPCAM ERCC2 EZH2 FANCA FANCB FANCC FANCL FANCM FH FLCN KIT MAX MEN1 MET NF1 NF2 NSD1 PALB2 PRKAR1A PTCH1 PTEN RAD51C RUN XI SBDS SDHAF2 SDHB SMARCB1 STK11 5UFU TMEM127 WRN XPA XPC This chart shows all 98 cancer susceptible genes included in this new test.
(64) Epigenetic alterations also play a role: another Fanconi gene, Fanconi anemia complementation group F (FANCF), can occasionally be inactivated by somatic methylation.
Estrogen receptoralpha, BRCA1, and FANCF promoter methylation occur in distinct subsets of sporadic breast cancers.
As an adaptor protein, FANCF interacts with the FANCC/FANCE subunit through its N-terminal, and with the FANCA/FANCG subunit through its C-terminal.
The purpose of the present study was to provide evidence for the role of FANCF in determining the proliferation, migration and chemosensitivity of human breast cancer by assaying cell function after FANCF knockdown.
Antibodies against FANCF and FANCD2 were from Abcam Inc.
The FANCF shRNA expression vector was used to achieve specific down-regulation of FANCF.
Then, cells were transfected with the pSilencer 4.1-CMV (Ambion) control shRNA vector (control shRNA, 20 mM) or pSilencer 4.1-CMV FANCF shRNA vector (FANCF shRNA, 20 mM) using Lipofectamine 2000 (Invitrogen, USA) according to the manufacturer's instructions.
Cells were transfected with control or FANCF shRNA for 24 and 48 h, and then treated with Dox at different concentrations (0.1, 1, 5, 10, 20, and 40 nM) for 24 h.
To determine the effect of FANCF shRNA on cell migration and invasion, cells were treated with FANCF shRNA for 48 h in medium containing 10% FCS.
FANCF expression was suppressed in breast cancer cells by RNA interference (RNAi)
Recently published studies have reported improved survival associated with loss of hMLH1 expression (regulated by methylation) in advanced ovarian cancer (21) and that demethylation of FANCF leads to cisplatin resistance in ovarian cancer patients (22).